We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

KS Clearly Not a Conventional Neoplasm

  • Daniel Liberthson, PhD
Mar 1, 1999
Volume: 
8
Issue: 
3
  • Sarcoma

SAN FRANCISCO—“Kaposi’s sarcoma (KS) conforms
very poorly to conventional notions about cancer,” Donald Ganem,
MD, of the University of California, San Francisco, said at a
conference on globally emerging viral infections. “It’s
properly classified as in the gray zone between proliferative
hyperplasia and frank neoplasm.”

Histologically, unlike typical cancers derived from the clonal
outgrowth of a single cell, KS tumors have three phases: a
proliferative component of mainly spindle-shaped cells probably
derived from endothelium, an inflammatory component made up of many
different cells of lymphoid and other origins, and a highly aberrant
angiogenic component of slit-like neovascular spaces that give the
lesion its red-purple color.

“Epidemiology started us thinking that a virus is involved in
KS,” Dr. Ganem said. Although KS became prevalent in the West in
conjunction with AIDS, it was evidently not caused by HIV, as it
existed in Africa in HIV-negative people.

The search for agents or cofactors led to the discovery in 1994 of a
virus named KS-associated herpes virus (KSHV), or human herpes virus
8 (HHV8), that is present in KS tumors. Using an immunofluorescence
test for one KSHV component, latency-associated nuclear antigen
(LANA), the prevalence of KSHV was found to be 1% to 2% in healthy US
blood donors, 30% to 35% in HIV-positive homosexual men, 3% to 4% in
HIV-positive women, and 2% to 3% in HIV-positive hemophiliacs.

A more sensitive commercial test that used immunofluorescence on the
lytic cycle showed seropositivity of 5% to 6% among Western blood
donors, 50% to 60% in HIV-positive gay men, and 95% to 96% in KS patients.

Asymmetry in Sexual Transmission

The asymmetry in sexual transmission of KSHV, shown by the much
higher seropositivity in gay men than in women, is unique among
sexually transmitted diseases, he said. Because the viral genome is
recovered from semen in less than 1% of HIV-positive men with KSHV
but is highly prevalent in saliva, oral-anal contact, which is more
prevalent in gay men, may explain this disparity.

In Africa and the Mediterranean, KS is endemic, and HIV-negative KS
is 10 to 20 times more common than in the US. Seroprevalence of KSHV
in Africa is 60% to 80% of the general population: Prepubertal
children are often seropositive, and prevalence increases with
increasing age. That a very important component of infection in
Africa occurs before the onset of sexual activity indicates nonsexual
modes of transmission in the first decade of life and thereafter, as
well as sexual modes later on.

This difference from the largely sexual transmission in the United
States is not understood. Nonetheless, he said, “in every
culture around the globe, there is a very strong linkage between
seropositivity for KSHV and the incidence of KS.”

At the individual level, seropositivity for KSHV increases the risk
of KS in those with HIV. Studies of young healthy gay men showed that
all of the KS cases occurred in HIV-positive men and none in
HIV-negative individuals. Among those seropositive for both HIV and
KSHV at entry to the studies, after 10 years, 40% to 50% developed
KS, a three- to fourfold higher rate than among men initially
seronegative for KSHV.

“If you are infected with both viruses and get no effective
treatment for either virus,” Dr. Ganem said, “after 10
years you have a 50% risk of developing KS. That is strong evidence
that infection with KSHV both antedates the neoplasm and is
predictive of an increased risk of KS.”

The weight of this evidence, Dr. Ganem concluded, “supports the
notion that KSHV is necessary but not sufficient for KS development;
you also need HIV or some other predisposing condition.”

The contribution of HIV may be only to create an immunodeficiency
state, allowing progression to tumor, a view supported by the fact
that cyclosporine use in renal transplants is also linked with the
development of KS.

It is also possible that HIV makes some specific genetic contribution
to the lesion, since in vitro studies have shown that products from
HIV-infected cells can act as a growth factor in cell cultures
derived from the KS tumor. “At this moment, school is out on
exactly what is the contribution of HIV to KS,” Dr. Ganem said,
“but in my view HIV-induced immunodeficiency may cause not the
decline of immune surveillance against tumor cells but rather the
loss of control of the lytic infection by KSHV.”

There are homologs between KSHV and other herpesviruses, but there
are also genes unique to KSHV, many of which have distant homologs in
host cell genomes that regulate some aspects of immune function.
These homologs may play a role in the disease.

“Pathogenesis is going to be more complicated than in other
tumor viruses because the neoplasm is not a traditional tumor,”
Dr. Ganem said, “but if we break down the viral gene expression
program into its proliferative, inflammatory, and angiogenic
components, we may discover what each contributes to the lesion.”

Related Articles

  • Clofarabine and Cladribine May Help Combat Ewing Sarcoma
  • Soft-Tissue Sarcoma Margin Classifying Systems Can Differ in Determining Recurrence Risk
  • Novel Agent Fails to Show Sufficient Activity in Recurrent Osteosarcoma
  • Lurbinectedin Effective in Early Trial of Advanced Ewing Sarcoma
  • Aftercare in Sarcoma Should Incorporate Time- and Risk-Adjusted Strategies

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.